BoB@JPM: Tom Chalberg, Ph.D., Genascence

Business Of Biotech

We love to hear from our listeners. Send us a message.

Recorded in-person at the JP Morgan Healthcare Conference in San Franscisco, this episode finds Matt Pillar and Ben Comer exploring the evolution of gene therapy with Dr. Tom Chalberg, Founder, Chairman, & CEO at Genascence. We discuss ATMPS' transition from treating rare diseases to addressing common conditions like osteoarthritis, share insights on the delivery mechanism and regulatory challenges in the space, and get into the nuts and bolts of the Genascence partnership strategy.

The 2025 BoB@JPM series is supported by Alston & Bird, whose national health care and life sciences practice has more than 100 attorneys actively involved and integrated across the full spectrum of legal disciplines including regulatory, compliance, public policy, transactional, corporate governance, securities, FDA, biotechnology, intellectual property, government investigations, and litigation practice areas. Learn more at www.alston.com.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Chapters

1. BoB@JPM: Tom Chalberg, Ph.D., Genascence (00:00:00)

2. Driving Gene Therapy Innovation in Biotech (00:00:04)

3. Advancing Gene Therapy for Public Health (00:12:17)

4. Navigating Challenges in Gene Therapy (00:19:40)

5. Investor Relations and Funding Strategies (00:27:39)

6. Developing Gene Therapy for Osteoarthritis (00:40:57)

7. Networking and Strategic Partnerships in Biotech (00:46:33)